Drug intelligence / Profile preview

E5555 + diltiazem

Development stage
Unknown
Lead developer
Eisai
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

E5555 is an investigational drug (not described in the provided sources; based on external knowledge it is a selective protease-activated receptor-1 [PAR-1] antagonist developed for cardiovascular indications). Diltiazem is a non-dihydropyridine calcium channel blocker used to treat hypertension (high blood pressure), angina (chest pain), and certain heart arrhythmias. It works by inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells during depolarization. This action relaxes blood vessels and reduces the workload on the heart while increasing coronary blood flow. Diltiazem is approved for use as an antihypertensive agent and antianginal agent[1][2][3][4][5][6].

Brand names
CardizemCardizem CDCardizem LACartia XTDilacor XRDilt-CDDiltia XTDilt-XRDiltzacMatzim LATaztia XTTiazac
Other names
benzothiazepine derivative (for diltiazem)
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)F2R (Protease-activated receptor 1)

Beyond the preview

Go deeper on E5555 + diltiazem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E5555 + diltiazem.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call